Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The use of muscle relaxants is an indispensable in the general anesthesia but is prone to
accidents, which are often related to residual muscle relaxant. Therefore, how to timely and
effectively eliminate the residual effect of muscle relaxants after surgery has become an
urgent clinical problem. Rocuronium is a non-depolarizing muscle relaxant that is primarily
metabolized by the liver. Patients with liver dysfunction can affect the metabolic process of
rocuronium, thereby delaying the recovery of muscle relaxation. Sugammadex (SUG) is a novel
specific antagonist of aminosteroid muscle relaxants, which can effectively antagonize muscle
relaxants at different depths. However, whether liver dysfunction affects the antagonistic
effect of SUG against rocuronium has not been reported yet. Therefore, the investigators
hypothesize that with the increase of patients' liver Child-Pugh grade, the recovery time of
rocuronium antagonized by the same dose of SUG after surgery will be prolonged, and the
incidence of muscle relaxation residual will be increased in the short term.